Scholar Rock’s (SRRK) Outperform Rating Reiterated at Wedbush

Wedbush reissued their outperform rating on shares of Scholar Rock (NASDAQ:SRRK) in a research report released on Monday,Benzinga reports. They currently have a $58.00 price target on the stock.

Several other research firms have also recently issued reports on SRRK. Cantor Fitzgerald reiterated an “overweight” rating on shares of Scholar Rock in a research report on Thursday, June 18th. Citigroup upped their price target on shares of Scholar Rock from $58.00 to $60.00 and gave the stock a “buy” rating in a research note on Friday, August 7th. Barclays increased their price target on shares of Scholar Rock from $53.00 to $55.00 and gave the company an “overweight” rating in a report on Friday, May 8th. BMO Capital Markets reissued an “outperform” rating and set a $76.00 price objective on shares of Scholar Rock in a report on Friday, August 7th. Finally, Canaccord Genuity Group initiated coverage on shares of Scholar Rock in a research report on Monday, April 20th. They set a “buy” rating and a $62.00 target price on the stock. Four equities research analysts have rated the stock with a Strong Buy rating, twelve have given a Buy rating and one has assigned a Sell rating to the stock. According to data from MarketBeat, Scholar Rock has an average rating of “Buy” and an average price target of $56.79.

Scholar Rock Stock Performance

Shares of SRRK stock opened at $53.82 on Monday. The company has a market cap of $6.55 billion, a price-to-earnings ratio of -15.60 and a beta of 0.69. The stock has a 50 day simple moving average of $50.48 and a 200-day simple moving average of $48.01. Scholar Rock has a 12-month low of $27.07 and a 12-month high of $58.49. The company has a current ratio of 8.64, a quick ratio of 8.64 and a debt-to-equity ratio of 0.71.

Scholar Rock (NASDAQ:SRRK) last posted its quarterly earnings results on Thursday, August 6th. The company reported ($0.84) EPS for the quarter, meeting the consensus estimate of ($0.84). During the same period last year, the firm earned ($0.98) earnings per share. On average, equities analysts forecast that Scholar Rock will post -3.26 EPS for the current year.

Insider Buying and Selling

In other news, Director Joshua Reed sold 3,053 shares of the firm’s stock in a transaction on Wednesday, July 1st. The stock was sold at an average price of $53.74, for a total value of $164,068.22. Following the completion of the transaction, the director owned 19,518 shares in the company, valued at $1,048,897.32. This trade represents a 13.53% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available through the SEC website. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, Director Katie Peng sold 5,446 shares of Scholar Rock stock in a transaction on Wednesday, July 1st. The stock was sold at an average price of $53.88, for a total value of $293,430.48. Following the transaction, the director directly owned 34,301 shares of the company’s stock, valued at $1,848,137.88. This trade represents a 13.70% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Insiders have sold 17,149 shares of company stock valued at $923,108 in the last three months. 10.30% of the stock is owned by insiders.

Institutional Trading of Scholar Rock

Several large investors have recently modified their holdings of the business. IFP Advisors Inc raised its position in shares of Scholar Rock by 294.1% during the 4th quarter. IFP Advisors Inc now owns 603 shares of the company’s stock worth $27,000 after purchasing an additional 450 shares during the last quarter. Caitong International Asset Management Co. Ltd purchased a new position in Scholar Rock during the fourth quarter worth $30,000. Summit Securities Group LLC acquired a new position in shares of Scholar Rock in the fourth quarter worth $31,000. Allworth Financial LP purchased a new stake in shares of Scholar Rock in the second quarter valued at $35,000. Finally, EverSource Wealth Advisors LLC lifted its position in shares of Scholar Rock by 151.3% in the fourth quarter. EverSource Wealth Advisors LLC now owns 872 shares of the company’s stock valued at $38,000 after acquiring an additional 525 shares in the last quarter. 91.08% of the stock is currently owned by institutional investors and hedge funds.

Key Stories Impacting Scholar Rock

Here are the key news stories impacting Scholar Rock this week:

• Positive Sentiment: Wedbush rated Scholar Rock “Outperform,” adding a constructive Wall Street view to the stock and potentially supporting investor confidence. Scholar Rock Earns Outperform Rating from Wedbush
• Positive Sentiment: HC Wainwright maintained a “Buy” rating and $65 price target for Scholar Rock. The target remains above the stock’s recent trading level, suggesting potential upside if the company meets its development and commercialization objectives.
• Neutral Sentiment: Reported short interest was zero shares as of August 11, unchanged from the prior report. The resulting zero-day days-to-cover figure provides no evidence of meaningful short-selling pressure, but the data may reflect a reporting or data-quality issue.
• Negative Sentiment: HC Wainwright lowered its EPS forecasts across multiple periods: Q3 2026 to $(0.84) from $(0.82), Q4 2026 to $(0.78) from $(0.75), FY2026 to $(3.29) from $(3.21), FY2027 to $(2.45) from $(2.32), FY2028 to $(0.86) from $(0.77), FY2029 to $0.35 from $0.40, and FY2030 to $1.40 from $1.43. These revisions indicate expectations for slower earnings improvement, despite the continued Buy rating.

Scholar Rock Company Profile

Scholar Rock is a clinical-stage biotechnology company focused on the discovery and development of protein therapeutics that selectively target growth factors involved in disease processes. The company’s research platform is designed to modulate endogenous growth factor activation and signaling with high specificity, aiming to restore normal biological function across a range of disorders. Scholar Rock’s approach is distinguished by its emphasis on engineering antibodies and biologics that interact with growth factor precursors or latent complexes rather than the active form, potentially offering improved safety and efficacy profiles.

The company’s lead program, SRK-015 (appercept), is an investigational monoclonal antibody targeting the activation of latent myostatin proproteins and is being evaluated for the treatment of spinal muscular atrophy (SMA).